The Albany Gazette - Tharimmune to Present at the Microcap Conference 2025

Albany - 10.04. 2025 - 09:00:34

NYSE - LSE

RBGPF	100%	60.27	$
CMSC	1.73%	22.6	$
RELX	6.65%	48.54	$
SCS	8.2%	10.61	$
AZN	2.79%	66.76	$
BP	6.42%	27.9	$
BTI	1.64%	40.21	$
GSK	1.02%	34.48	$
NGG	3.79%	65.21	$
RIO	5.92%	55.61	$
RYCEF	1.08%	9.3	$
CMSD	1.63%	22.75	$
BCE	0.62%	21	$
BCC	8.64%	98.44	$
VOD	4.55%	8.58	$
JRI	4.34%	11.99	$

Tharimmune to Present at the Microcap Conference 2025

TECHNOLOGY 27.01.2025

Tharimmune to Present at the Microcap Conference 2025

BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.

Text size:

Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.

Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time

Investors interested in meeting with management can register for the conference here.

About Tharimmune

Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.

Contacts

Tharimmune, Inc.
ir@tharimmune.com

Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614

Contact Information

Tirth Patel
Alliance Advisors IR
tpatel@allianceadvisors.com
1-212-201-6614

SOURCE: Tharimmune Inc.

View the original press release on ACCESS Newswire

(W.Walker--TAG)

Featured

Amazon satellite launch scrubbed due to weather

Weather prevented a rocket carrying the first batch of Amazon satellites designed to compete with Elon Musk's Starlink from lifting off Wednesday, in a setback for the planned Project Kuiper network.

ALT5 Sigma Launches Crypto-as-a-Service Offering, Enabling FINRA Members, Banks, and Credit Unions to Rapidly Deploy Compliant Digital Asset Trading Capabilities

ALT5 joins the Securities Industry and Financial Markets Association (SIFMA)

Amazon to launch first batch of satellites rivaling Musk

The US retail giant Amazon is preparing to launch Wednesday its first full batch of Project Kuiper satellites, marking a crucial milestone in the battle with Elon Musk's Starlink to provide high-speed internet.

Trump's NASA chief pick says will 'prioritize' Mars mission

NASA will prioritize sending astronauts to Mars, President Donald Trump's pick to lead the US space agency said Wednesday, shifting focus beyond a long-planned return to the Moon -- but insisting both were achievable.